TY - JOUR
T1 - Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins
AU - Embers, Monica E.
AU - Budgeon, Lynn R.
AU - Culp, Timothy D.
AU - Reed, Cynthia A.
AU - Pickel, Martin D.
AU - Christensen, Neil D.
N1 - Funding Information:
This study was supported by Public Health Service grant R01CA47622 from the National Cancer Institute, National Institutes of Health, and the Jake Gittlen Memorial Golf Tournament.
PY - 2004/1/26
Y1 - 2004/1/26
N2 - A peptide derived from the human papillomavirus type 16 (HPV-16) minor capsid protein, L2, has previously been reported to induce cross-neutralizing antibodies in mice. In this report, four HPV L2 peptides, including the HPV-16 peptide and its HPV type 6 and 11 homologues, along with extended peptides containing a conserved set of amino acids, were used to immunize rabbits and mice. Antibody responses were evaluated for specificity and ability to neutralize viral infection in vitro with a quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR) assay. All peptide immunizations resulted in cognate and cross-peptide reactivity, but this did not translate equally into recognition of full-length protein, VLP, or neutralization of virus in vitro. This report provides the first evidence of cross-neutralization of authentic HPV by antiserum to L2 peptides. Comparison of the anti-peptide serum reactivity, especially with regard to neutralization of virus, indicates that the extended peptides may offer more potential to induce adequate responses for cross-protective immunity.
AB - A peptide derived from the human papillomavirus type 16 (HPV-16) minor capsid protein, L2, has previously been reported to induce cross-neutralizing antibodies in mice. In this report, four HPV L2 peptides, including the HPV-16 peptide and its HPV type 6 and 11 homologues, along with extended peptides containing a conserved set of amino acids, were used to immunize rabbits and mice. Antibody responses were evaluated for specificity and ability to neutralize viral infection in vitro with a quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR) assay. All peptide immunizations resulted in cognate and cross-peptide reactivity, but this did not translate equally into recognition of full-length protein, VLP, or neutralization of virus in vitro. This report provides the first evidence of cross-neutralization of authentic HPV by antiserum to L2 peptides. Comparison of the anti-peptide serum reactivity, especially with regard to neutralization of virus, indicates that the extended peptides may offer more potential to induce adequate responses for cross-protective immunity.
UR - http://www.scopus.com/inward/record.url?scp=1642452616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642452616&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2003.08.037
DO - 10.1016/j.vaccine.2003.08.037
M3 - Article
C2 - 14741159
AN - SCOPUS:1642452616
VL - 22
SP - 670
EP - 680
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 5-6
ER -